medigraphic.com
Instituto Nacional de Salud Pública

2007, Number S3

<< Back Next >>

salud publica mex 2007; 49 (S3)

Seroprevalence of antibodies against poliovirus type 1 in Mexican children

Ruiz-Gómez J, Valdespino JL, Olaiz-Fernández G, Arias-Toledo E, Sepúlveda J

Language: Spanish
References: 46
Page: 361-369
PDF size: 200.63 Kb.


ABSTRACT

Objective. To analyze the frequency and distribution of the prevalence of antibodies against the poliomyelitis type 1 virus in children 1-9 years old in Mexico. Material and Methods. Antibodies against poliovirus type 1 (neutralization method) were studied in 6 270 sera selected from the 24 232 sera from children one to nine years old, collected by the 2000 National Health Survey (ENSA 2000) that was conducted from November 1999 to June 2000. Results. Overall seroprevalence was 99.3% (95%CI: 99.1-99.7). Using bivariate analysis, absence of antibodies was shown to be associated with illiteracy (OR= 1.5, p=0.002) and low household income (OR= 1.4, p=0.0487), while those children having access to social security (OR= 0.41 p=0.04) had a higher likelihood of having protective antibodies. Conclusions. The vaccination program activities conducted by health institutions have been successful in the control and eradication of the disease. However, a note of caution is necessary since the expansion of data reveals that although seroprevalence of antibodies has an upper limit of 99.3%, 0.7% of children (roughly 190 000) are susceptible to developing the disease. Most of these children live in the southern regions of the country.


REFERENCES

  1. Di Lonardo A, Buttinelli G, Amato C, Novello F, Ridolfi B, Fiore L. Rapid methods for identification of poliovirus isolates and determination of polio neutralizing antibody titers in human sera. J Virol Methods 2002;101(1-2):189-196.

  2. Georgopoulou A, Markoulatos P, Spyrou N, Vamvakopoulos NC. Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications. J Clin Microbiol 2000;38(12):4337-4342.

  3. Morens D, Pallansch MA. Epidemiology. In: Rotbart HA, ed. Human enterovirus infections. Washington: ASM Press, 1995:3-23.

  4. Melnick JL. Enteroviruses: poliovirus, coxsackieviruses, echoviruses and newer enteroviruses. Virology 1996:655-712.

  5. Reimerink JH, van der Avoort HG, van Loon AM, Koopmans MP. Genetic basis for immunological aberrations in poliovirus Sabin serotype 3 strains imported in the netherlands. J Clin Microbiol 1999;37(8):2393-2398.

  6. Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus vaccination after eradication: issues and challenges. Bull World Health Organ 2000;78(3):347-357.

  7. Hull HF, Ward NA, Hull BP, Milstien JB, de Quadros C. Paralytic poliomyelitis: seasoned strategies, disappearing disease. Lancet 1994;343(8909):1331-1337.

  8. Maurice J. Polio eradication—the last and toughest 1%. Bull World Health Organ 2001;79(6):582.

  9. Mascareñas A, Salinas J, Tasset-Tisseau A, Ortiz E. Polio intensive immunization week in Mexico: an economic burden assessment. Abstract no. 384. World Congress of Pediatric Infectious Diseases-WSPID. Santiago de Chile, Chile, Nov 2002.

  10. Ruiz-Gómez J. Inmunoprofilaxia de la poliomielitis. Vacunas, ciencia y salud. En: Escobar-Gutiérrez A, Valdespino-Gómez JL, Sepúlveda-Amor J, eds. México: Secretaría de Salud, 1992:131-142.

  11. Cardenas-Ayala VM, Vilchis-Licon H, Stetler HC, et al. Risk factors for the presistence of wild poliovirus transmission in Sinaloa, Mexico, 1984-1986. Bull Pan Am Health Organ 1988;22(3):227-239.

  12. Ruiz-Gómez J, Tapia-Conyer R, Salvatierra B, et al. Seroepidemiología de la poliomielitis en México. Salud Publica Mex 1992;34:168-176.

  13. Hovi T. Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 2001;19(17-19):2268-2272.

  14. Swennen B, Levy J. Oral poliomyelitis vaccine: time to change? Vaccine 2001;19(17-19):2262-2267.

  15. Bompart F. Vaccination strategies for the last stages of global polio eradication. Indian Pediatr 2005;42(2):163-169.

  16. John TJ. A developing country perspective on vaccine-associated paralytic poliomyelitis. Bull World Health Organ 2004;82(1):53-57; discussion 57-58.

  17. Sutter RW, Cochi SL, Melnick JL. Live attenuated poliovirus vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999:364-408.

  18. Sutter RW, Suleiman AJ, Malankar P, et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000;343(11):767-773.

  19. Grotto I, Handsher R, Gdalevich M, et al. Decline in immunity to polio among young adults. Vaccine 2001;19(30):4162-4166.

  20. Kew O, Morris-Glasgow V, Landaverde M, et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 2002;296(5566):356-359.

  21. Shulman LM, Handsher R, Yang CF, et al. Resolution of the pathways of poliovirus type 1 transmission during an outbreak. J Clin Microbiol 2000;38(3):945-952.

  22. Kojouharova M, Zuber PL, Gyurova S, et al. Importation and circulation of poliovirus in Bulgaria in 2001. Bull World Health Organ 2003;81(7):476-481.

  23. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis 1997;175(Suppl 1):S165-S172.

  24. Khare S, Bhatia R, Kumari S, Datta KK. Virologic surveillance of poliomyelitis in Delhi. Indian Pediatr 1996;33(9):746-750.

  25. Sokhey J, Sharma B, Singh H, Sood D. Isolation of poliovirus from cases of acute flaccid paralysis. Indian Pediatr 1996;33(11):917-920.

  26. WHO. Manual for the virological investigation of polio. Geneva: WHO/EPI/GEN, 1997;97(01).

  27. Edevag G, Wahren B, Osterhaus AD, Sundqvist VA, Granstrom M. Enzyme-linked immunosorbent assay-based inhibition test for neutralizing antibodies to polioviruses as an alternative to the neutralization test in tissue culture. J Clin Microbiol 1995;33(11):2927-2930.

  28. Simhon A, Lifshitz A, Abed Y, Lasch EE, Schoub B, Morag A. How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants. Int J Epidemiol 1990;19(1):164-168.

  29. Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci 1995;754:289-299.

  30. Ruiz-Gómez J, Caloca-García M, Longega-Escobio P. Anticuerpos humorales, coproanticuerpos y excreción viral en recién nacidos inmunizados con la vacuna antipoliomielítica. Salud Publica Mex 1979;21:127-134.

  31. Slater PE, Orenstein WA, Morag A, et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990;335(8699):1192-1195; discussion 1196-1198.

  32. Böttiger M. Polio immunity to killed vaccine: an 18-year follow-up. Vaccine 1990;8:443-445.

  33. Patriarca PA. Poliomyelitis in selected african and asian countries. Public Health Rev 1993;21(1-2):91-98.

  34. Patriarca PA, Foege WH, Swartz TA. Progress in polio eradication. Lancet 1993;342(8885):1461-1464.

  35. Plotkin S, Vidor E. Poliovirus vaccine-Inactivated. In: Plotkin S, Orenstein W, eds. Vaccines. United States of America: Elsevier Inc., 2004: 625-650.

  36. Manor Y, Handsher R, Halmut T, et al. Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority. J Clin Microbiol 1999;37(6):1670-1675.

  37. Unidad de Inmunización. Vigilancia de la poliomielitis en las Américas. Bol Sem Pol 2006;21(37).

  38. Dirección General de Epidemiología. Sistema de vigilancia epidemiológica de poliomielitis y parálisis flácida aguda. Mexico: Secretaría de Salud, 2006. Disponible en http://www.dgepi.salud.gob.mx/boletin/2006/sem40/pdf/ind_pfa1.pdf.

  39. WHO. Fourth informal consultation on the polio laboratory network. Geneva: Department of Vaccines and other Biologicals. Geneva: WHO, 1999.

  40. Guillot S, Otelea D, Delpeyroux F, Crainic R. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. Vaccine 1994;12(6):503-507.

  41. De L, Nottay B, Yang CF, Holloway BP, Pallansch M, Kew O. Identification of vaccine-related polioviruses by hybridization with specific RNA probes. J Clin Microbiol 1995;33(3):562-571.

  42. Advisory Committee on Polio Eradication—standing recommendations for responding to circulating polioviruses in polio-free areas. Wkly Epidemiol Rec 2005;80(38):330-331.

  43. Hogg K, Hogg G, Lester R, Uren E. Immunity to poliomyelitis in Victorians. Aust N Z J Public Health 2002;26(5):432-436.

  44. Seibil VB, Malyshkina LP, Lavrova IK, Efimova VF, Sadovnikova VN. State of collective immunity to poliomyelitis in Moscow donors. Zh Mikrobiol Epidemiol Immunobiol 2002(6):43-47.

  45. Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA 1996;275(21):1639-1645.

  46. Diedrich S, Schreier E. Status of immunity against poliomyelitis. Polio serosurvey in 1993. Dtsch Med Wochenschr 1995;120(8):239-244.




2020     |     www.medigraphic.com